Do males 30-50 years of age with chronic epilepsy and on long-term anticonvulsant medication have lower-than-expected risk of developing coronary heart disease?

Epilepsia

Volumn 39, Issue 3, 1998, Pages 326-330

  Nakken, Karl Otto ^a   Kornstad, Stig ^b  

^a National Center for Epilepsy   (Norway)

^b Hamana Medical Center   (Norway)

Author keywords

Antiepileptic drugs; Coronary heart disease; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHOLESTEROL; CLONAZEPAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BODY FAT; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; EPILEPSY; FITNESS; HUMAN; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADIPOSE TISSUE; ADULT; ANTICONVULSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY CONSTITUTION; CHOLESTEROL; CHRONIC DISEASE; CORONARY DISEASE; EPILEPSY; HEALTH STATUS; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHYSICAL FITNESS; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 0031913103     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01381.x     Document Type: Article

References (28)

1. Lindén V. Myocardial infarction in epileptics. Br Med J 1975;2:87.
2. Livingston S. Phenytoin and serum cholesterol. Br Med J 1976;1: 586.
3. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia: inadvertent effects of drugs in clinical practice. JAMA 1992;267:961-8.
4. Calandre EP, Porta BS, de la Calzada DG. The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients. Epilepsia 1992;33:154-7.
5. Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI. Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 1985;28:615-8.
6. Brown DW, Ketter TA, Crumlish J, Post RM. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992;12:431-7.
7. Haussler MR. Vitamin D: mode of action and biomedical applications. Nutr Rev 1974;32:257.
8. Annegers JF, Elveback LR, Labarthe DR, Hauser WA. Ischemic heart disease in patients with epilepsy. Epilepsia 1976;17:11-4.
9. Kasaskis EJ, Kuo C-S, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction: characterization of two distinct clinical syndromes. Arch Intern Med 1992;152:186-91.
10. Bjørholt PG, Nakken KO, Røhme K, Hansen H. Leisure time habits and physical fitness in adults with epilepsy. Epilepsia 1990;31:83-7.
11. Wilhelmsen L, Bjure J, Ekstrøm-Jodal B. Nine years' follow-up of a maximal exercise test in a random population sample of middleaged men. Cardiology 1981;68(suppl 2): 1-8.
12. Lie H, Mundal R, Erikssen J. Coronary risk factors and incidence of coronary death in relation to physical fitness. Seven-year follow-up study of middle-aged and elderly men. Eur Heart J 1985;6:147-57.
13. Morris JN, Pollard P, Everitt MG, Chave SPW. Vigorous exercise in leisure time: protection against coronary heart disease. Lancet 1980;206:1201-10.
14. Paffenbarger R, Hyde RT, Wing AL, Steinmetz CH. A natural history of athleticism and cardiovascular health. JAMA 1984;252: 491-5.
15. Nakken KO, Bjørholt PG, Johannessen SI, Løyning T, Lind E. Effect of physical training on aerobic capacity, seizure occurrence, and serum level of antiepileptic drugs in adults with epilepsy. Epilepsia 1990;31:88-94.
16. Kannel WB, Castelle WP, Gordon T, McNamara PM. The Framingham study. Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann Intern Med 1971;74:1-12.
17. Cooper KH. Cooper clinic, coronary risk factor charts. Running without fear. New York: M. Evans and Company, 1985:209-20.
18. Kornstad S, Lie H. Hjertetest. Erfaringer fra norsk helsesenter. Tidsskr Nor Lægeforen 1988;108:2246-9.
19. Pollock M, Wilmore JH, Fox SM, Exercise in health and disease. Philadelphia: W.B. Saunders Company, 1984:155-225.
20. Zeitlhofer J, Doppelbauer A, Tribl G, Leitha T, Deecke L. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Investig 1993;71:574-8.
21. Isojärvi JIT, Pakarinen AJ, Myllylä VV. Serum lipids during car-bamazepine medication. A prospective study. Arch Neural 1993;50:590-3.
22. Eirís JM, Lojo S, Del Río MC, Novo I, Bravo M, Pavón P, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155-7.
23. Hauser WA, Annegers JF, Elveback LR. Mortality in patients with epilepsy. Epilepsia 1980;21:399-412.
24. Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984;25:699-704.
25. Muuronen A, Kaste M, Nikkilä EA. Tolppanen E-M. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J 1985;291:1481-3.
26. Klenerman P, Sander JWAS, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long term residential care. J Neurol Neurosurg Psychiatr 1993;56:149-52.
27. Nashef L, Sander JWAS, Shorvon SD. Mortality in epilepsy. In: Pedley TA, Meldrum BS, eds. Recent advances in epilepsy, vol. 6. Edinburgh: Churchill Livingstone, 1995;271-87.
28. Neuspiel DR, Kuller LH. Sudden and unexpected natural death in childhood and adolescence. JAMA 1985;254:1321-5.